CG-806 for Acute Myeloid Leukemia and High-Risk MDS
Trial Summary
What is the purpose of this trial?
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
Research Team
Rafael Bejar, MD, PhD
Principal Investigator
Aptose Biosciences Inc.
Eligibility Criteria
This trial is for adults over 18 with relapsed or stubborn Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), who can't have intense chemo or a transplant. They should be fairly active, able to swallow pills, and not on other experimental drugs recently.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
CG-806 is given orally in ascending doses to determine the maximum tolerated dose or recommended Phase 2 dose
Cohort Expansion
Up to 50 patients are enrolled at the recommended dose to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CG-806
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aptose Biosciences Inc.
Lead Sponsor